News for PLSE Stock

Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference Pulse Biosciences’ Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025 Pulse Biosciences’ Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025 Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer Pulse Biosciences’ Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium Pulse Biosciences’ Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference Pulse Biosciences, Inc. Announces Planned Redemption of Warrants Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024 Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024 Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation Pulse Biosciences, Inc. Announces the Closing of its Rights Offering Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering Pulse Biosciences, Inc. Announces Commencement of Rights Offering Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000 Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting Pulse Biosciences Enhances Executive Leadership Team Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000 Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024 Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results Pulse Biosciences Announces Plans to Initiate a Rights Offering Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024 Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023 Pulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery Pulse Biosciences Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit Pulse Biosciences’ First Study in a Surgical Application of Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Two Poster Presentations at the American Thyroid Association Annual Meeting Pulse Biosciences to Present at Gilmartin Group Emerging Growth Showcase Pulse Biosciences Clarifies Details of Recent S-3 Filing Pulse Biosciences Reports Business Updates and Second Quarter 2023 Financial Results Pulse Biosciences Schedules Second Quarter 2023 Financial Results Conference Call for August 10, 2023 Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results Pulse Biosciences, Inc. Announces Planned Redemption of Warrants Pulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer Pulse Biosciences Announces $65 Million Private Placement Pulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023 Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results Pulse Biosciences Schedules Fourth Quarter & Full Year 2022 Financial Results Conference Call for March 30, 2023 Pulse Biosciences Announces Its Novel Nanosecond Pulsed Field Ablation System Will Be Highlighted at the 2023 AF Symposium Pulse Biosciences Reports Third Quarter 2022 Financial Results Pulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022 Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation Pulse Biosciences Reports Second Quarter 2022 Financial Results Pulse Biosciences Receives FDA 510(k) Clearance of Expanded Energy Settings for use with the CellFX® System Pulse Biosciences Schedules Second Quarter 2022 Financial Results Conference Call for August 10, 2022 Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering Pulse Biosciences, Inc. Announces Changes to its Rights Offering Pulse Biosciences Reports First Quarter 2022 Financial Results Pulse Biosciences, Inc. Announces Commencement of Rights Offering Pulse Biosciences Schedules First Quarter 2022 Financial Results Conference Call for May 11, 2022 Pulse Biosciences to Present New Data on Nano-Pulse Stimulation Procedure for Sebaceous Hyperplasia and for Focal Epithelial Hyperplasia at 2022 American Society of Laser Medicine and Surgery Annual Conference Pulse Biosciences, Inc. Announces Rights Offering Pulse Biosciences Reports Fourth Quarter & Full Year 2021 Financial Results Pulse Biosciences Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call for March 31, 2022 Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer Pulse Biosciences Provides an Update on Recent FDA 510(k) Submission Pulse Biosciences to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Pulse Biosciences Announces Preliminary Fourth Quarter and Full Year 2021 Financial and Operational Results Pulse Biosciences to Participate in the Stephens Annual Investment Conference Pulse Biosciences Reports Third Quarter 2021 Financial Results Pulse Biosciences to Present at the Stifel 2021 Virtual Healthcare Conference Pulse Biosciences Schedules Third Quarter 2021 Financial Results Conference Call for November 15, 2021 Pulse Biosciences Appoints Laureen DeBuono to Its Board of Directors Pulse Biosciences to Participate in the H.C. Wainwright Global Investment Conference Pulse Biosciences Announces Appointment of Mitchell E. Levinson as Chief Strategy Officer Pulse Biosciences Reports Second Quarter 2021 Financial Results Pulse Biosciences Schedules Second Quarter 2021 Financial Results Conference Call for August 9, 2021 Pulse Biosciences Announces $50 Million Private Placement Pulse Biosciences Announces First CellFX® Procedure Performed in Canada Pulse Biosciences Announces Health Canada Approval for CellFX® System Pulse Biosciences to Participate in the Jefferies Healthcare Conference Pulse Biosciences® Presents Clinical Study Results of Nano-Pulse Stimulation™ Technology to Clear Benign Lesions at the American Society for Laser Medicine and Surgery (ASLMS) 2021 Virtual Annual Conference Pulse Biosciences Reports First Quarter 2021 Financial Results Pulse Biosciences Schedules First Quarter 2021 Financial Results Conference Call for May 10, 2021 Pulse Biosciences to Present Consumer Research on Patient Perceptions of Benign Lesion Clearance at American Academy of Dermatology VMX Meeting 2021 Pulse Biosciences to Participate in Upcoming Investor Conferences Pulse Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch Pulse Biosciences Announces Start of Controlled Launch of the CellFX System® Pulse Biosciences Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call for February 22, 2021 Pulse Biosciences, Inc. Announces At-The-Market Equity Offering Program Pulse Biosciences Announces FDA Clearance for the CellFX® System Pulse Biosciences Announces CE Mark Approval for CellFX® System Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress Pulse Biosciences, Inc. Announces Redemption of Warrants Pulse Biosciences Grants Equity Incentive Awards To New Employees Pulse Biosciences Presents Update on Nano-Pulse Stimulation™ Technology at Prestigous Energy-Based Devices and Aesthetic Dermatology Conference Pulse Biosciences to Participate in Upcoming Investor Conferences Pulse Biosciences Schedules Third Quarter 2020 Financial Results Conference Call for November 9, 2020 Pulse Biosciences Announces Presentation of Clinical Results Using Nano-Pulse Stimulation Technology for the Clearance of Skin Lesions at the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting Pulse Biosciences Announces FDA IDE Approval and Initiation of Sebaceous Hyperplasia Study Pulse Biosciences Announces Receipt of MDSAP Certification